In the phase 2, single-arm, open-label trial ROAR, the BRAF cohort included 43 adult patients with BRAFV600E-mutated CCA with metastatic, locally advanced, unresectable, or recurrent disease that had progressed on prior therapy [50]. The gene discussed is BRAF; the disease is cholangiocarcinoma.